Psychiatric diagnosis

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

Monday, July 26, 2021 - 9:10pm

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • Leveraging the experience gained from the development and marketing of a treatment for Alzheimers disease, Eisai aims to establish the Eisai Dementia Platform.
  • Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

Monday, July 26, 2021 - 1:30pm

Boca Raton, FL, July 26, 2021 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD). The announcement is accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients.  

Key Points: 
  • The announcement is accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients.
  • "This is the first time in my career that I have seen positive changes, and in such a short time frame.
  • "Apparent fiber density decreases with axonal degeneration, and this is always seen in Alzheimer's disease patients.
  • In the Phase 1b study, we demonstrated XProTM significantly decreased biomarkers of neuroinflammation in Alzheimers patients.

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Monday, July 26, 2021 - 1:00pm

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.

Key Points: 
  • These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.
  • The OVERTURE study demonstrated that gamma frequency neuro-modulation led to a significant reduction in brain atrophy in AD patients.
  • Accelerated brain atrophy is associated with cognitive decline and loss of function in AD patients and is a driver of mortality and morbidity in Alzheimers disease progression.
  • Cognito Therapeutics is a clinical-stage neuro-physiology company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimers disease.

Lighthouse Autism Center and Cerberus Announce Strategic Partnership

Monday, July 26, 2021 - 1:00pm

Lighthouse Autism Center (Lighthouse or the Company) today announced a strategic investment by an affiliate of Cerberus Capital Management (Cerberus), a global leader in alternative investing.

Key Points: 
  • Lighthouse Autism Center (Lighthouse or the Company) today announced a strategic investment by an affiliate of Cerberus Capital Management (Cerberus), a global leader in alternative investing.
  • Lighthouse is a leading provider of center-based applied behavioral analysis (ABA) services for children diagnosed with autism spectrum disorder.
  • Nicholas Scola, Partner at Abry Partners, added: "We are excited to continue our partnership with the Lighthouse team and welcome the support of Cerberus.
  • Headquartered in South Bend, Indiana, Lighthouse is a leading provider of center-based autism behavioral health services for children diagnosed with autism spectrum disorder.

Alzheimer's Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer's

Monday, July 26, 2021 - 3:00pm

The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.

Key Points: 
  • The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
  • Recent research shows that Alzheimer'salso causes subtle early changes in aspects of behaviour such as sleep, speech, interactions, and movement.
  • While undetectable to the human eye, these changes can now be picked up by commercially available digital technologies.
  • Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Improving Air Quality Reduces Dementia Risk, Multiple Studies Suggest

Monday, July 26, 2021 - 3:00pm

While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.

Key Points: 
  • While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.
  • "But what's exciting is we're now seeing data showing that improving air quality may actually reduce the risk of dementia.
  • Air Quality Improvement May Slow Cognitive Decline and Reduce Dementia Risk in Older U.S. Women
    Although studies have found that improved air quality is associated with better respiratory health and longer life expectancy, it's unknown if improved air quality can also improve brain health.
  • Association of air quality reduction with incident dementia: effects of natural course and hypothetical air pollutant interventions using g-computation.

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

Monday, July 26, 2021 - 1:42pm

ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.

Key Points: 
  • Following the review, the Agency met with the Company on July 22, 2021, and granted the company permission to begin evaluation of IkT-148009 in Parkinson's patients.
  • "The extension of our Phase 1 study of IkT-148009 for the treatment of Parkinson's disease into patients is an important milestone for Inhibikase.
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
  • Inhibikase is currently evaluating the safety, tolerability and pharmacokinetics of IkT-148009in older and healthy subjects and Parkinson's patients.

SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome

Monday, July 26, 2021 - 1:30pm

TEL AVIV, Israel, July 26, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110.

Key Points: 
  • TEL AVIV, Israel, July 26, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110.
  • The company is currently in contact with two clinical sites that will potentially host and conduct the clinical study.
  • Tourette Syndrome (TS) is a movement and neurobehavioral disorder characterized by motor and vocal chronic tics with onset before age 18.
  • SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI-110 in a randomized, double-blind, placebo controlled, cross-over study.

FTC Votes to Reverse Course on Repeal of Fabric Care Labels

Saturday, July 24, 2021 - 10:07pm

Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.

Key Points: 
  • Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.
  • After careful consideration, I believe the record supports retaining the Care Labeling Rule and that it should not be rescinded.
  • Many individuals and small businesses opposed the repeal, emphasizing that buyers rely on labels to help extend the life of their clothes.
  • The Commission voted 5-0 to issue a statement to notify the public that it will not repeal the Care Labeling Rule, as previously proposed.

FTC Votes to Reverse Course on Repeal of Fabric Care Labels

Saturday, July 24, 2021 - 10:07pm

Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.

Key Points: 
  • Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.
  • After careful consideration, I believe the record supports retaining the Care Labeling Rule and that it should not be rescinded.
  • Many individuals and small businesses opposed the repeal, emphasizing that buyers rely on labels to help extend the life of their clothes.
  • The Commission voted 5-0 to issue a statement to notify the public that it will not repeal the Care Labeling Rule, as previously proposed.